Glycopyrronium Bromide (Inhalation capsule)
Generic Details
Generic Name
Glycopyrronium Bromide Inhalation Capsule
Other Names
- Seebri Breezhaler
Drug Class
- Anticholinergic
Chemical Formula
C19H28BrNO3
Molecular Weight
412.34 g/mol
Mechanism of Action
- Blocks muscarinic receptors, leading to bronchodilation
Indications
- Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Common Dosage Forms
- Inhalation capsule
Typical Dosage
- 50 mcg once daily
Pediatric Dosage
- Not established
Geriatric Dosage
- No dosage adjustment required
Side Effects
- Dry mouth
- Sore throat
- Cough
- Headache
- Constipation
Contraindications
- Hypersensitivity to glycopyrronium or any component of the product
Pregnancy Category
- Category C - Risk cannot be ruled out
Lactation Safety
- Limited data available; exercise caution or avoid
Drug Interactions
- Anticholinergic medications
- Beta-agonists
Overdose Symptoms
- Severe dry mouth
- Blurred vision
- Urinary retention
Antidote for Overdose
- Physostigmine
Storage Conditions
- Store at room temperature (20-25°C)
Pharmacokinetics
- Absorption: Rapidly absorbed following inhalation
- Distribution: Widely distributed in the body
- Metabolism: Metabolized in the liver
- Excretion: Mainly excreted in urine
Precautions
- Use with caution in patients with urinary retention or narrow-angle glaucoma
Warnings
- Not indicated for the treatment of acute episodes of bronchospasm
Others
- Avoid getting the powder in eyes; it may cause eye pain or discomfort